Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03867253 · ClinicalTrials.gov registry record · Phase 2
Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Oryzon Genomics S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03867253 is a Phase 2 study that has completed, run by Oryzon Genomics S.A.. The registered enrollment target is 24 participants.
The verdict
NCT03867253, a Phase 2 study, has completed, sponsored by Oryzon Genomics S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.
Interventions
- DRUG Placebo
- DRUG ORY-2001 Low dose
- DRUG ORY-2001 High dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-05-16 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03867253
The ClinicalTrials.gov registry entry for NCT03867253 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oryzon Genomics S.A., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03867253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03867253 about?
NCT03867253 is a clinical study titled "Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease". This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.
What is the current status of trial NCT03867253?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2019-05-16. Estimated completion is 2020-11-12.
What interventions are being tested in trial NCT03867253?
The interventions under investigation include: Placebo (DRUG), ORY-2001 Low dose (DRUG), ORY-2001 High dose (DRUG).
Who is sponsoring clinical trial NCT03867253?
This trial is sponsored by Oryzon Genomics S.A., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.